⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Supplementary Figure 6 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Michelle Melino Wen Juan Tu Helle Bielefeldt‐Ohmann Martina Proctor Taniya Ahuja John Vandermeide Amanda L. Bain Gahyathiri Nallan Sal Lee Goh Thiru Prasanna Jane E. Dahlstrom Mariska Miranda Ramesh Kumar Chaudhary Aravind Anandam Sumit Chaudhary Jonathan T. Seal Debottam Sinha Shaoqian Zhang Tam Hong Nguyen Sriganesh Srihari Günter Härtel Amy Ives Laeeq Malik Desmond Yip Michelle Nottage Melissa Eastgate Sudha Rao

View Full Paper

Ask AI

Bookmark

Share

Key Points

EZH2 and NF-κB co-localization promotes pro-oncogenic gene expression in triple-negative breast cancer.
Supplementary Figure demonstrates the role of EZH2 in activating pathways that drive metastasis in TNBC.
Assessment of PI3K-mTOR inhibition provides new insights into overcoming immunotherapy resistance in cancer.
Understanding EZH2's interactions can guide therapeutic strategies against triple-negative breast cancer.

Abstract

Supplementary Figure 6. EZH2 co-localizes with NF-κB to activate pro-oncogenic gene expression in TNBC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Melino et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a65 https://doi.org/10.1158/1535-7163.30255319

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025
2Supplementary Figure 7 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025
3Supplementary Figure 4 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025
4Supplementary Figure 5 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025
5Supplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025

More related papers

Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025
Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025
Supplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer2025